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Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial
Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial
Alon Eisen, MD; Christian T. Ruff, MD, MPH; Eugene Braunwald, MD; Rose A. Hamershock, MA; Basil S. Lewis, MD;
Christian Hassager, MD; Tze-Fan Chao, MD; Jean Yves Le Heuzey, MD; Michele Mercuri, MD; Howard Rutman, MD; Elliott M. Antman, MD;
Robert P. Giugliano, MD, SM
Background-—Digoxin is widely used in patients with atrial ﬁbrillation despite the lack of randomized controlled trials.
Observational studies report conﬂicting results regarding its association with mortality, perhaps because of residual confounding
by the presence of heart failure (HF).
Methods and Results-—In the ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-
Thrombolysis in Myocardial Infarction 48) trial, clinical outcomes of patients with atrial ﬁbrillation with and without HF were
examined by baseline digoxin use during a median follow-up of 2.8 years. HF was deﬁned at baseline as prior or current clinical
stage C or D HF. Of 21 105 patients enrolled, 6327 (30%) were treated with digoxin at baseline. Among patients without HF
(n=8981), digoxin use (20%) was independently associated with sudden cardiac death (adjusted hazard ratio, 1.51; 95% CI, 1.10–
2.08), with no signiﬁcant interaction by age, sex, left ventricular ejection fraction, renal function, or concomitant medications
(P>0.05 for each). Consistent results were observed using propensity matching (adjusted hazard ratio for sudden cardiac death,
1.90; 95% CI, 1.36–2.65). Among patients with HF (n=12 124), digoxin use (37%) was associated with an increase in all-cause
death, cardiovascular death, sudden cardiac death, and death caused by HF/cardiogenic shock (P<0.01 for each), but not with
noncardiovascular death, stroke/systemic embolism, or myocardial infarction.
Conclusions-—In this observational analysis of patients with atrial ﬁbrillation without investigator-reported HF, digoxin use was
signiﬁcantly associated with sudden cardiac death. While residual confounding cannot be excluded, the association between
digoxin use and worse clinical outcomes highlights the need to examine digoxin use, particularly when prescribed to control heart
rate in patients with atrial ﬁbrillation in a randomized trial.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00781391. ( J Am Heart Assoc. 2017;6:
e006035. DOI: 10.1161/JAHA.117.006035.)
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D igoxin, a positive inotropic agent that blocks atri-oventricular conduction, is widely used in patients
with atrial ﬁbrillation (AF), despite the lack of randomized
clinical trials in this population.1 In patients with AF and
concomitant heart failure (HF), digoxin may be prescribed
for both of these indications, while in patients without HF,
it is used mainly as a rate-control therapy.2,3 The 2014 AF
guidelines of the American Heart Association/American
College of Cardiology/Heart Rhythm Society recommend
using digoxin to control resting heart rate in patients with
reduced left ventricular ejection fraction (LVEF) (class I,
level of evidence C), and also in combination with b-
blockers or nondihydropyridine calcium channel blockers,
regardless of HF status (class IIa, level of evidence B).4,5
The 2016 European Society of Cardiology AF guidelines
recommend using digoxin in the long-term management of
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AF patients with LVEF above or below 40% (class I, level
of evidence B).3
Conﬂicting data exist regarding adverse outcomes that are
associated with digoxin use in patients with AF.6–16 While
several retrospective studies and meta-analyses have demon-
strated an association between digoxin use and all-cause
mortality, cardiovascular death, and sudden cardiac death
(SCD),6–13 other studies have not found a compelling
association.14–16 These contradictory results can be attrib-
uted to the nature of observational studies and to digoxin
prescription biases. It remains unclear whether the associa-
tion between digoxin and worse clinical outcome is causal or
may be the result of residual confounding, mainly dominated
by the presence of HF.
Thus, we aimed to examine the association between
digoxin use and clinical outcomes (fatal and nonfatal events)
in a large contemporary cohort of patients with AF both with
and without HF.
Methods
This study represents an analysis from the ENGAGE AF-TIMI
48 (Effective Anticoagulation With Factor Xa Next Generation
in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)
trial. The ENGAGE AF-TIMI 48 trial was a 3-group, random-
ized, double-blind, double-dummy multinational trial that
compared 2 dosing regimens of the oral factor Xa inhibitor
edoxaban with warfarin in 21 105 patients with AF
(NCT00781391).17 A detailed description of the study
population, study design, and results of the trial have been
published.17,18 In brief, eligible patients were 21 years and
older with ECG evidence of AF within 12 months before
randomization and had a CHADS2 score ≥2 and planned
anticoagulation. Key exclusion criteria were AF attributable
to a reversible cause, presence of a mechanical valve or
moderate-severe mitral stenosis, increased risk of bleeding,
recent acute coronary syndrome or stroke within 30 days
before randomization, severe renal insufﬁciency (creatinine
clearance <30 mL/min), and life expectancy <12 months.
Patients with any class of HF could be enrolled provided they
were clinically stable at the time of randomization. The
protocol and amendments were approved by the ethics
committee at each participating center. All patients provided
written informed consent.
Digoxin Use and HF Deﬁnition
Digoxin use was captured by the treating physician in the
concomitant medication case report form at baseline before
enrollment. HF was deﬁned as the presence or history of
clinical stage C or D HF according to the American College of
Cardiology/American Heart Association criteria.19 This
includes structural heart disease with prior or current
symptoms of HF, such as shortness of breath, fatigue, and
decreased exercise tolerance (stage C), or refractory HF
requiring specialized interventions (stage D). Investigators
classiﬁed HF at baseline as “systolic,” “diastolic,” or “both,”
provided the New York Heart Association functional class, and
when available, reported the most recent LVEF before
randomization.
Clinical End Points
End points of this analysis were as deﬁned in the trial
protocol17,18 and examined during a median follow-up of
2.8 years. Deaths in the ENGAGE AF-TIMI 48 trial were
adjudicated by an independent clinical end point committee
without knowledge of randomized anticoagulant treatment
assignment. Deaths were categorized as cardiovascular or
noncardiovascular. Cardiovascular death included SCD,
deﬁned as an unexpected death that was either witnessed
(occurring within 60 minutes from the onset of new symp-
toms, in the absence of a clear cause other than cardiovas-
cular) or unwitnessed (within 24 hours of being observed
alive, in the absence of preexisting progressive circulatory
failure or other noncardiovascular causes of death), death
caused by HF or cardiogenic shock, or other cardiovascular
causes (eg, systemic embolic event, pulmonary embolism,
atherosclerotic vascular disease excluding coronary, related
to coronary revascularization, or other).17,18 Nonfatal events
included stroke or systemic embolism, HF hospitalization, or
myocardial infarction (MI).
Clinical Perspective
What is New?
• In this observational analysis of patients with atrial ﬁbrilla-
tion with or without heart failure (HF), digoxin use, after
adjusting for multiple confounders, was associated with
worse clinical outcomes. In patients with HF, it was
associated with all-cause death, cardiovascular death,
sudden cardiac death, HF death, and HF hospitalizations.
In patients without HF, it was signiﬁcantly associated with
sudden cardiac death.
• While the results in patients with HF might be caused by
residual confounding, the study highlights the need to
examine digoxin use in patients with atrial ﬁbrillation
without HF in a randomized controlled trial.
What are the Clinical Implications?
• Given the availability of other rate-control agents, until the
safety of digoxin in patients with atrial ﬁbrillation without HF
has been established, the use of the drug in this population
should be undertaken with great care, if at all.
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Statistical Analysis
Baseline characteristics of patients by digoxin treatment and
HF status were compared between groups using chi-square
tests for categorical variables and Kruskal–Wallis tests for
continuous variables. Three methods were used to examine
the association between digoxin use and clinical outcomes.
The ﬁrst used the Cox proportional hazards model. Clinical
outcomes were examined in the intention-to-treat population,
including all events between randomization and the end of the
study treatment period, whether occurring on or off study
drug. Variables in the multivariable models were based on the
baseline characteristics, with a P<0.1 in the univariate model,
omitting colinear variables and adding variables that were
judged to be of clinical importance. All multivariable analyses
were adjusted for the following baseline characteristics: age;
sex; weight; region; race; creatinine; pattern of AF (persistent/
permanent versus paroxysmal); hypertension; diabetes melli-
tus; prior stroke/transient ischemic attack; coronary artery
disease; prior MI; peripheral arterial disease; smoking (current
or past); increased risk of falling; LVEF; HF (when appropriate);
mitral valve disease; aortic valve disease; prior electrical
cardioversion; left ventricular hypertrophy on ECG; use of a
vitamin K antagonist ≥60 consecutive days at any time before
enrollment; lipid-lowering drugs; class I, class II (b-blockers),
or class III antiarrhythmics; renin-angiotensin-aldosterone
system inhibitors; randomization group; heart rate; chronic
obstructive pulmonary disease; and diuretic use. Clinical
outcomes were examined separately in patients with or
without HF. Among patients with HF, clinical outcomes were
further examined in patients with systolic HF, diastolic HF, or
both.
The second method was propensity matching, which was
performed on key baseline characteristics to balance digoxin
use at baseline in patients with or without HF. Matching was
performed using a 1:1 nearest neighbor approach without
replacement with a caliper of 0.1 of the SD. In a sensitivity
analysis of the propensity model, we explored a trimmed
model eliminating patients with extreme propensity scores
(<5th or >95th percentile) to reduce the potential impact of
unmeasured confounders.
The third method utilized inverse probability treatment
weighting (IPTW), which uses stablized weights calculated
with the inverse value of the propensity scores.
A sensitivity analysis using digoxin as a time-varying
covariate examined the association between digoxin use
during the trial and clinical outcomes in patients without HF.
Digoxin use was reported at each study visit (every 3 months)
and was regarded as a time-dependent variable using 2
methods. In the ﬁrst method, if digoxin was not present at
baseline but was started during follow-up, the patient was
regarded as taking digoxin throughout the trial (digoxin “on”),
while in the second method, the patient was regarded as
taking or not taking digoxin per the status of digoxin use every
3 months (digoxin “on/off”).
Results are presented as hazard ratios (HRs) and 95%
CIs, with P<0.05 considered signiﬁcant. Propensity score
matching was performed using R Studio. All other analyses
were performed in SAS Enterprise Guide 7.1 (SAS Institute
Inc).
Results
Overall Population
Of the 21 105 patients who were enrolled in the ENGAGE AF-
TIMI 48 trial, 6327 patients (30.0%) were treated with digoxin
at baseline. Compared with patients not treated with digoxin,
patients taking digoxin were slightly younger, more often
female, and were more likely to have persistent/permanent
AF, HF at baseline, and lower LVEF (P<0.001 for each; other
baseline variables that differed between the 2 groups are
shown in Table 1).20–22
Digoxin use was associated with all-cause mortality (annual
rate, 5.2% versus 3.6%; adjusted HR, 1.22 [95% CI, 1.12–
1.34]), cardiovascular death, SCD, death caused by HF or
cardiogenic shock, and HF hospitalizations (Table 2). No
signiﬁcant association was observed between digoxin use at
baseline and noncardiovascular death, stroke or systemic
embolism, or MI (Table 2). There was no effect of randomized
treatment on the relationship between digoxin use and clinical
outcomes (data not shown).
Patients With HF at Baseline
A total of 12 124 patients (57.4%) had HF reported at
baseline. Of these, 4502 patients (37.1%) were treated with
digoxin at baseline. Compared with patients not treated with
digoxin, patients treated with digoxin were younger and more
likely to have permanent AF, lower LVEF, worse New York
Heart Association class, and higher heart rate and be treated
with diuretics (P<0.001 for each, Table S1).
In patients with HF, digoxin use was associated with an
increase in all-causemortality (adjustedHR, 1.27; 95%CI, 1.14–
1.41), cardiovascular death (adjusted HR, 1.32; 95% CI, 1.16–
1.49), SCD (adjusted HR, 1.45; 95% CI, 1.21–1.74), death
caused by HF or cardiogenic shock (adjusted HR, 1.44; 95% CI,
1.13–1.83), and HF hospitalizations (adjusted HR, 1.21; 95% CI,
1.08–1.36) (Table 2). There was no signiﬁcant association
between digoxin use at baseline and noncardiovascular death,
stroke or systemic embolism, or MI (Table 2). Consistent
qualitatively similar results were demonstrated using propen-
sity matching and IPTW for all end points except for
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Table 1. Baseline Characteristics by Digoxin Use at Baseline
Characteristic, No. (%)
Digoxin
n=6327 (30%)
No Digoxin
n=14 778 (70%) P Value Total (N=21 105)
Age, median (IQR), y 71 (63–77) 72 (65–78) <0.001 72 (64–78)
Female sex 2556 (40.4) 5484 (37.1) <0.001 8040 (38.1)
Weight, mean (SD), kg 82.0 (20.6) 84.7 (20.0) <0.001 83.9 (20.2)
Region* <0.001
North America 1154 (18.2) 3527 (23.9) 4681 (22.2)
Latin America 977 (15.4) 1684 (11.4) 2661 (12.6)
Western Europe 733 (11.6) 2503 (16.9) 3236 (15.3)
Eastern Europe 2315 (36.6) 4829 (32.7) 7144 (33.8)
Asia-Pacific and South Africa 1148 (18.1) 2235 (15.1) 3383 (16.0)
White race (n=21 104) 4892 (77.3) 12 175 (82.4) <0.001 17 067 (80.9)
Type of atrial fibrillation (n=21 099) <0.001
Paroxysmal 713 (11.3) 4653 (31.5) 5366 (25.4)
Persistent 1424 (22.5) 3444 (23.3) 4868 (23.1)
Permanent 4189 (66.2) 6676 (45.2) 10 865 (51.5)
Qualifying risk factor
Congestive heart failure 4502 (71.2) 7622 (51.6) <0.001 12 124 (57.4)
Hypertension requiring treatment 5853 (92.5) 13 901 (94.1) <0.001 19 754 (93.6)
Age ≥75 y 2279 (36.0) 6195 (41.9) <0.001 8474 (40.2)
Diabetes mellitus 2329 (36.8) 5295 (35.8) 0.17 7624 (36.1)
Prior stroke or transient ischemic attack 1706 (27.0) 4267 (28.9) 0.005 5973 (28.3)
CHADS2 score
†
Mean (SD) 2.9 (1.0) 2.8 (1.0) <0.001 2.8 (1.0)
4 to 6 1531 (24.2) 3237 (21.9) <0.001 4768 (22.6)
CHA2DS2-VASc score
†
Mean (SD) 4.4 (1.4) 4.3 (1.4) 0.06 4.3 (1.4)
4 to 9 4471 (70.7) 10 448 (70.7) 0.96 14 919 (70.7)
HAS-BLED score
†
Mean (SD) 2.4 (0.9) 2.6 (1.0) <0.001 2.5 (1.0)
≥3 2643 (41.8) 7159 (48.4) <0.001 9802 (46.4)
Coronary artery disease (n=21 102) 2004 (31.7) 5019 (34.0) 0.001 7023 (33.3)
Prior myocardial infarction 704 (11.1) 1729 (11.7) 0.23 2433 (11.5)
Ejection fraction‡ <0.001
<30% 398 (8.6) 384 (3.5) 782 (5.0)
30% to 39% 673 (14.6) 848 (7.7) 1521 (9.8)
40% to 49% 1058 (22.9) 1810 (16.5) 2868 (18.4)
≥50% 2488 (53.9) 7905 (72.2) 10 393 (66.8)
NYHA III or IV§ (n=11 988) 1220 (27.4) 1415 (18.8) <0.001 2635 (22.0)
Peripheral arterial disease (n=21 096) 211 (3.3) 630 (4.3) 0.002 841 (4.0)
Former/current smoker (n=21 098) 532 (8.4) 1020 (6.9) <0.001 1552 (7.4)
COPD 626 (9.9) 1155 (7.8) <0.001 1781 (8.4)
Mitral valve disease (n=20 983) 2276 (36.2) 4972 (33.8) 0.001 7248 (34.5)
Aortic valve disease (n=21 014) 907 (14.4) 2227 (15.1) 0.17 3134 (14.9)
Continued
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noncardiovascular death (matched HR, 1.21; 95% CI, 1.00–
1.46) and MI (matched HR, 0.75; 95% CI, 0.59–0.95) (Table 3).
Among patients with systolic HF (n=5027), including 2875
patients with isolated systolic and 2152 patients with both
systolic and diastolic HF, 34.3% were treated with digoxin at
baseline. Among patients with isolated diastolic HF (n=4150),
41.3% were treated with digoxin at baseline. In patients with
any systolic HF, digoxin use was associated with all-cause
death, cardiovascular death, SCD, and death caused by HF or
cardiogenic shock, with the latter being the strongest
association (adjusted HR, 2.20; 95% CI, 1.48–3.29)
(Table S2). In patients with isolated diastolic HF, a similar
qualitative association between digoxin use and worse
outcomes was observed, with the exception of death caused
by HF or cardiogenic shock (adjusted HR, 1.17; 95% CI, 0.79–
1.72 [P interaction by HF type=0.01]) (Table S2).
Patients Without HF at Baseline
A total of 8981 patients (42.6%) did not have HF at baseline.
Of these, 1825 patients (20%) were treated with digoxin at
baseline. Compared with patients not treated with digoxin,
patients treated with digoxin were of similar age (median
75 years), were more likely to have permanent AF and higher
heart rate, and were less likely to be treated with beta
blockers (Table S1).
In patients without HF, digoxin use was signiﬁcantly
associated with SCD (adjusted HR, 1.51; 95% CI, 1.10–2.08
[P=0.01]) but not all-cause mortality, other causes of death,
or nonfatal events (Table 2; Figure 1). Qualitatively similar
results were demonstrated using IPTW (HR for SCD, 1.47;
95% CI, 1.02–2.10 [P=0.04]), propensity matching (HR for
SCD, 1.90; 95% CI, 1.36–2.65 [P<0.001]) (Table 3), and a
Table 1. Continued
Characteristic, No. (%)
Digoxin
n=6327 (30%)
No Digoxin
n=14 778 (70%) P Value Total (N=21 105)
Prior electrical cardioversion for AF (n=21 104) 995 (15.7) 2796 (18.9) <0.001 3791 (18.0)
Charlson comorbidity index, mean (SD) 2.9 (1.1) 2.8 (1.1) <0.001 2.8 (1.1)
Heart rate, mean (SD), bpm (n=21 074) 77.1 (14.2) 73.0 (13.8) <0.001 74.3 (14.0)
Hypertrophy per ECG (n=20 950) 1311 (20.8) 2126 (14.5) <0.001 3437 (16.4)
Vitamin K antagonist experiencedk (n=21 104) 3918 (61.9) 8523 (57.7) <0.001 12 441 (59.0)
Medication at randomization
Aspirin (n=21 101) 1630 (25.8) 4550 (30.8) <0.001 6180 (29.3)
Lipid-lowering 2558 (40.4) 7524 (50.9) <0.001 10 082 (47.8)
Antiarrhythmics
Class I 95 (1.5) 798 (5.4) <0.001 893 (4.2)
Class II (b-blockers) 4119 (65.1) 9865 (66.8) 0.02 13 984 (66.3)
Class III 588 (9.3) 2546 (17.2) <0.001 3134 (14.8)
Class IV 629 (9.9) 1276 (8.6) 0.002 1905 (9.0)
Diuretics 4445 (70.3) 8211 (55.6) <0.001 12 656 (60.0)
RAAS inhibitor 4313 (68.2) 9593 (64.9) <0.001 13 906 (65.9)
CrCl, median (IQR), mL/min 70.4 (53.5–93.0) 70.3 (53.9–91.4) 0.37 70.3 (53.8–91.9)
Dose reduction at randomization 1779 (28.1) 3577 (24.2) <0.001 5356 (25.4)
Randomized treatment
High-dose edoxaban 2078 (32.8) 4957 (33.5) 0.10 7035 (33.3)
Low-dose edoxaban 2073 (32.8) 4961 (33.6) 7034 (33.3)
Warfarin 2176 (34.4) 4860 (32.9) 7036 (33.3)
Data are expressed as number (percentage) unless otherwise indicated. bpm indicates beats per minute; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance; IQR,
interquartile range; RAAS, renin-angiotensin-aldosterone system.
*Percentages are for each region except for the Total column.
†CHADS2 score—see reference
20; CHA2DS2-VASc score—see reference
21; HAS-BLED score—see reference.22
‡Ejection fraction was unknown for 5541 patients (digoxin, 1710 patients; no digoxin, 3831 patients).
§New York Heart Association (NYHA) functional class at baseline was reported only in patients with heart failure.
kVitamin K antagonist experienced denotes ≥60 consecutive days of treatment with a vitamin K antagonist at any time before enrollment.
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trimmed propensity score (1.37; 95% CI, 0.96–1.95
[P=0.08]).
There was no signiﬁcant heterogeneity in the association
between digoxin use and SCD across subgroups including
age, sex, region, weight, renal function, b-blocker use, and
heart rate (Table 4). In addition, in patients without HF with
LVEF ≥50% (n=5525), digoxin use was associated with SCD
(adjusted HR, 1.58; 95% CI, 1.03–2.43) but not other causes
of death including death caused by HF or cardiogenic shock
(adjusted HR, 0.85; 95% CI, 0.35–2.06 [Figure 2]).
In a sensitivity analysis using digoxin as a time-variant
covariate, digoxin use remained a signiﬁcant predictor of SCD
(HR, 5.53; 95% CI, 1.66–18.41 in the digoxin “on” analysis
and HR, 4.45; 95% CI, 1.37–14.44 in the digoxin “on/off”
Table 2. Clinical Outcomes by Digoxin Use and HF Status at Baseline
End Point, No. (%/y)
Total (N=21 105) HF (n=12 124) No HF (n=8981)
Digoxin
(n=6327)
No Digoxin
(n=14 778)
Adjusted HR*
(95% CI)
Digoxin
(n=4502)
No Digoxin
(n=7622)
Adjusted HR*
(95% CI)
Digoxin
(n=1825)
No Digoxin
(n=7156)
Adjusted HR*
(95% CI)
All-cause death 899 (5.2) 1450 (3.6) 1.22 (1.12–1.34) 714 (5.9) 870 (4.2) 1.27 (1.14–1.41) 185 (3.6) 580 (2.9) 1.10 (0.92–1.31)
Cardiovascular
death
673 (3.9) 995 (2.4) 1.27 (1.14–1.41) 555 (4.6) 633 (3.0) 1.32 (1.16–1.49) 118 (2.3) 362 (1.8) 1.13 (0.91–1.41)
SCD 333 (1.9) 416 (1.0) 1.49 (1.27–1.74) 273 (2.3) 273 (1.3) 1.45 (1.21–1.74) 60 (1.2) 143 (0.7) 1.51 (1.10–2.08)
HF/cardiogenic
shock death
173 (1.0) 217 (0.5) 1.41 (1.14–1.76) 152 (1.3) 162 (0.8) 1.44 (1.13–1.83) 21 (0.4) 55 (0.3) 1.34 (0.77–2.33)
Noncardiovascular
death
226 (1.3) 455 (1.1) 1.10 (0.92–1.31) 159 (1.3) 237 (1.1) 1.12 (0.90–1.40) 67 (1.3) 218 (1.1) 1.04 (0.77–1.40)
Stroke/SSE 317 (1.9) 699 (1.8) 1.00 (0.87–1.16) 218 (1.9) 348 (1.7) 0.99 (0.83–1.18) 99 (2.0) 351 (1.8) 1.06 (0.84–1.33)
HF hospitalizations 688 (4.3) 1073 (2.8) 1.22 (1.10–1.36) 608 (5.5) 786 (4.0) 1.21 (1.08–1.36) 80 (1.6) 287 (1.5) 1.11 (0.85–1.45)
MI 124 (0.7) 319 (0.8) 0.91 (0.73–1.14) 86 (0.7) 175 (0.9) 0.85 (0.64–1.13) 38 (0.8) 144 (0.7) 1.08 (0.74–1.58)
SCD indicates sudden cardiac death; SSE, stroke or systemic embolism.
*Hazard ratios (HRs) are adjusted for age; weight; sex; region; race; creatinine; atrial ﬁbrillation type; heart failure (HF; for total HRs only); hypertension; diabetes mellitus; history of stroke
or transient ischemic attack; history of coronary artery disease; prior myocardial infarction (MI); history of peripheral artery disease; smoking status; increased risk of falling; left ventricular
ejection fraction; mitral valve disease; aortic valve disease; prior electrical cardioversion; left ventricular hypertrophy; previous use of vitamin K antagonists ≥60 days before randomization;
lipid-lowering medications; class I, II, or III antiarrhythmics; renin-angiotensin-aldosterone inhibitors; randomized treatment group; heart rate; history of chronic obstructive pulmonary
disease; and diuretic use at randomization.
Table 3. Digoxin Use in Patients With or Without HF at Baseline Using Propensity Matching and Inverse Probability Weighting
End Point
HF No HF
Propensity Matching*
HR (95% CI)
Inverse Probability Weighting
HR (95% CI)
Propensity Matching†
HR (95% CI)
Inverse Probability Weighting
HR (95% CI)
All-cause death 1.31 (1.19–1.43) 1.29 (1.15–1.44) 1.16 (0.98–1.36) 1.13 (0.92–1.38)
Cardiovascular death 1.34 (1.20–1.48) 1.33 (1.17–1.51) 1.22 (0.99–1.50) 1.11 (0.87–1.41)
SCD 1.58 (1.36–1.85) 1.46 (1.21–1.75) 1.90 (1.36–2.65) 1.47 (1.02–2.10)
HF/cardiogenic shock death 1.49 (1.21–1.84) 1.46 (1.14–1.86) 1.40 (0.78–2.50) 1.34 (0.75–2.38)
Noncardiovascular death 1.21 (1.00–1.46) 1.19 (0.93–1.51) 1.06 (0.81–1.38) 1.17 (0.82–1.65)
Stroke/SSE 0.87 (0.75–1.01) 1.00 (0.83–1.21) 0.84 (0.69–1.03) 0.97 (0.75–1.25)
HF hospitalizations 1.12 (1.02–1.24) 1.27 (1.12–1.43) 1.18 (0.91–1.51) 1.20 (0.89–1.63)
MI 0.75 (0.59–0.95) 0.95 (0.70–1.28) 0.83 (0.59–1.18) 1.08 (0.71–1.65)
HR indicates hazard ratio; MI, myocardial infarction; SCD, sudden cardiac death; SSE, stroke or systemic embolism.
*Included 4051 matched pairs based on age; sex; region; race; weight; atrial ﬁbrillation type; hypertension; diabetes mellitus; history of stroke or transient ischemic attack; history of
coronary artery disease; history of peripheral artery disease; increased risk of falling; left ventricular ejection fraction; prior electrical cardioversion; hypertrophy per ECG; pervious use of
vitamin K agonists for ≥60 days before randomization; lipid-lowering medications; class I, II, III, or IV antiarrhythmics; renin-angiotensin-aldosterone inhibitors; randomized treatment group;
diuretic use; aspirin use; dose adjustment; serum creatinine; heart rate; Charlson comorbidity index; and heart failure (HF) type.
†Included 1817 matched pairs based on age; sex; region; race; weight; atrial ﬁbrillation type; hypertension; diabetes mellitus; history of stroke or transient ischemic attack; history of
coronary artery disease; history of peripheral artery disease; increased risk of falling; left ventricular ejection fraction; prior electrical cardioversion; hypertrophy per ECG; pervious use of
vitamin K agonists for ≥60 days before randomization; lipid-lowering medications; class I, II, III, or IV antiarrhythmics; renin-angiotensin-aldosterone inhibitors; randomized treatment group;
diuretic use; aspirin use; dose adjustment; serum creatinine; heart rate; and Charlson comorbidity index.
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analysis) (Table S3). Digoxin was not independently associ-
ated with all-cause death, all cardiovascular death (including
both SCD and non-SCD), or noncardiovascular death in either
analysis (Table S3).
Discussion
In the current analysis from a large international cohort of
patients with AF, treatment with digoxin was common, with
more than a third of the patients with concomitant HF and a
ﬁfth of the patients without HF taking the agent. In the trial as
a whole, digoxin use was associated with increased all-cause
mortality, cardiovascular death, SCD, death caused by HF or
cardiogenic shock, and HF hospitalization. This association
was evident particularly among patients with HF. Importantly,
in patients without HF, digoxin use was signiﬁcantly associ-
ated with SCD. While the association between digoxin use and
clinical outcomes may be a result of residual confounding by
differences in comorbidities and treatment in patients with
HF, it is less likely to be inﬂuenced by these factors in patients
without HF.
Digoxin is widely used in patients with AF for several
indications. While in patients with concomitant HF it is used
both as a positive inotropic agent and as rate-control
therapy, in patients with AF without HF it is prescribed
primarily to achieve better rate control. As demonstrated in
this study and others,1,9,14 in patients with HF, digoxin is
prescribed to patients with more advanced HF, lower LVEF,
A
C
B
Figure 1. Kaplan–Meier curves of (A) all-cause death, (B) cardiovascular death, and (C) sudden cardiac death, by digoxin use at baseline and heart
failure (HF) status. P interaction between digoxin use and HF status is 0.16 (A), 0.14 (B), and 0.75 (C). CHF indicates congestive heart failure.
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Table 4. SCD by Digoxin Use in Subgroups of Patients Without Heart Failure
Subgroup
Patients,
No.
Digoxin SCD,
No. (%/y)
No Digoxin SCD,
No. (%/y)
Adjusted HR*
(95% CI) P Interaction
Age, y 0.36
<65 1665 7 (0.8) 24 (0.6) 1.11 (0.47–2.61)
65–74 2657 17 (1.0) 27 (0.5) 2.21 (1.17–4.15)
≥75 4659 36 (1.4) 92 (0.9) 1.39 (0.92–2.11)
Sex 0.85
Male 5517 38 (1.3) 97 (0.8) 1.55 (1.04–2.29)
Female 3464 22 (1.0) 46 (0.6) 1.46 (0.86–2.45)
Race 0.98
White 7115 43 (1.1) 108 (0.7) 1.52 (1.05–2.21)
Nonwhite 1865 17 (1.5) 35 (0.9) 1.51 (0.83–2.73)
Region 0.33
North America 2814 17 (1.0) 36 (0.6) 1.73 (0.95–3.15)
Latin America 975 10 (1.7) 37 (1.9) 0.77 (0.37–1.62)
Western Europe 1808 11 (1.2) 29 (0.7) 1.72 (0.85–3.49)
Eastern Europe 1719 9 (0.9) 19 (0.5) 1.83 (0.80–4.18)
Asia-pacific and South Africa 1665 13 (1.3) 22 (0.6) 2.11 (1.06–4.20)
Weight, kg 0.81
≤60 956 14 (1.9) 21 (1.1) 1.64 (0.83–3.25)
>60 8025 46 (1.0) 122 (0.7) 1.50 (1.04–2.14)
Type of AF 0.03
Paroxysmal 2928 2 (0.2) 44 (0.6) 0.21 (0.03–1.45)
Persistent/permanent 6048 58 (1.3) 99 (0.8) 1.77 (1.25–2.50)
LV ejection fraction 0.33
<50% 597 10 (2.5) 16 (1.3) 2.48 (1.06–5.81)
≥50% 5525 31 (1.1) 82 (0.6) 1.55 (1.01–2.37)
Charlson comorbidity index 0.45
≤Mean 5227 32 (1.1) 75 (0.6) 1.64 (1.07–2.52)
>Mean 3754 28 (1.2) 68 (0.8) 1.30 (0.82–2.05)
LV hypertrophy per ECG 0.55
Yes 737 9 (1.8) 22 (1.5) 1.23 (0.54–2.80)
No 8164 50 (1.1) 118 (0.6) 1.61 (1.15–2.25)
Heart rate at baseline, bpm 0.40
<80 6365 30 (0.9) 92 (0.6) 1.35 (0.89–2.05)
≥80 2596 30 (1.7) 49 (0.9) 1.77 (1.09–2.88)
b-Blockers at baseline 0.35
Yes 5313 36 (1.3) 87 (0.7) 1.72 (1.15–2.58)
No 3668 24 (1.1) 56 (0.7) 1.26 (0.77–2.08)
Diuretic use at baseline 0.38
Yes 3918 33 (1.3) 63 (0.7) 1.74 (1.12–2.71)
No 5063 27 (1.0) 80 (0.7) 1.31 (0.83–2.07)
Continued
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worse New York Heart Association functional class, and
greater burden of other comorbidities. As such, the associ-
ation between digoxin use and clinical outcomes in patients
with HF may be biased by residual confounding caused by
the baseline medical condition and concomitant medica-
tions.15 Adjusting for multiple confounders, propensity
matching, and IPTW may not fully account for this difference.
Thus, our results in patients with HF should be interpreted
with caution. In contrast, in patients without HF who are
presumably treated with digoxin as a rate-control therapy,
residual confounding may play a much smaller role. In these
patients, the association between digoxin use and SCD,
which was also demonstrated in propensity matching and
IPTW, was robust. Furthermore, given the possibility that
among patients who were categorized as not having HF at
baseline there were patients with undiagnosed HF, the
association between digoxin use and clinical outcomes was
also examined in a more homogenous group of patients
without HF and LVEF ≥50%. In these patients, not only did
the association between digoxin use and SCD remain
signiﬁcant, but the adjusted HRs were qualitatively similar.
Furthermore, these results were strengthened by the lack of
association between digoxin use and death caused by HF or
cardiogenic shock (Figure 2).
Table 4. Continued
Subgroup
Patients,
No.
Digoxin SCD,
No. (%/y)
No Digoxin SCD,
No. (%/y)
Adjusted HR*
(95% CI) P Interaction
CrCl, mL/min 0.96
≤60 3356 33 (1.7) 78 (1.1) 1.51 (0.98–2.33)
>60 5625 27 (0.8) 65 (0.5) 1.48 (0.94–2.35)
Randomized treatment 0.59
High-dose edoxaban 2938 20 (1.2) 45 (0.7) 1.70 (1.00–2.90)
Low-dose edoxaban 3055 12 (0.7) 44 (0.6) 1.13 (0.59–2.17)
Warfarin 2988 28 (1.6) 54 (0.8) 1.64 (1.02–2.64)
AF indicates atrial ﬁbrillation; bpm, beats per minute; CrCl, creatinine clearance; SCD, sudden cardiac death.
*Hazard ratios (HRs) are adjusted for age; weight; sex; region; race; creatinine; atrial ﬁbrillation type; hypertension; diabetes mellitus; history of stroke or transient ischemic attack; history
of coronary artery disease; prior myocardial infarction; history of peripheral artery disease; smoking status; increased risk of falling; left ventricular (LV) ejection fraction; mitral valve
disease; aortic valve disease; prior electrical cardioversion; LV hypertrophy; previous use of vitamin K antagonists ≥60 days before randomization; lipid-lowering medications; class I, II, or
III antiarrhythmics; renin-angiotensin-aldosterone inhibitors; randomized treatment group; heart rate; history of chronic obstructive pulmonary disease; and diuretic use at randomization.
Figure 2. Kaplan–Meier curve of sudden cardiac death (SCD) and death caused by heart failure (HF) or
cardiogenic shock, by digoxin use in patients without HF and left ventricular ejection fraction (LVEF) ≥50%
(n=5525). Log-rank P value for SCD=0.02; log-rank P value for death caused by HF or cardiogenic
shock=0.95. HR indicates hazard ratio.
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SCD is the single most common cause of death among
patients with AF, accounting for about a third of all
deaths.23–26 In a recent analysis from the ENGAGE AF-TIMI
48 trial, the cause for SCD was unknown in most cases and
an arrhythmia was documented in only a minority of SCD
events (11.5%).25 Digoxin is an important factor associated
with SCD in this population.25 The association between
digoxin use and SCD in patients with AF appears to be
more dominant in individuals without HF, yet the causality
is not clear and seems complex. Digoxin has a narrow
therapeutic range and is inﬂuenced by drug-to-drug inter-
actions, serum electrolyte concentrations, and renal func-
tion.3 In patients with AF, the majority of whom are elderly
with concomitant medically treated conditions, digoxin
concentration may ﬂuctuate. In this study, patients without
HF who were treated with digoxin were elderly (more than
half were ≥75 years) with a high burden of comorbidities
including diabetes mellitus and reduced renal function.
These characteristics may have predisposed them to
abnormal digoxin concentration, yet our results did not
show any heterogeneity for the risk of SCD by any of these
factors, perhaps owing to low statistical power. Whether the
concomitant use of b-blockers with digoxin in patients
without HF has a protective effect against SCD is not
known and it cannot be established from this observational
study. In addition, whether digoxin’s inotropic activity in
patients without HF can be harmful deserves further
research. Thus, revealing additional mechanisms of the
association between digoxin use and SCD in patients with
AF without HF is of interest.
This study has several clinical implications, mainly in
patients with AF without HF, in whom randomized studies
with digoxin are absent. In these patients, digoxin is usually
not prescribed as a ﬁrst-line therapy, but rather as an add-
on treatment with another rate-control agent. Indeed, in our
study, about 70% of the patients without HF treated with
digoxin were also treated with b-blockers or nondihydropy-
ridine calcium channel blockers. However, prescribing
digoxin as a single rate-control agent in patients with AF
without HF is not rare and may be the result of an adverse
event, such as bradycardia experienced with the other rate-
control therapies. Regardless of the reason for prescribing
digoxin in patients with AF without HF, our study empha-
sizes the concern with the use of therapy, which is not
supported by adequately sized randomized clinical trials.
Consistent with prior data,1,27 our ﬁndings highlight the
complex intersection between digoxin use, HF, and worse
clinical outcomes, and raise a concern of a possible
association between digoxin use and SCD. This study
highlights the unmet need for examining digoxin use in
patients with AF with, but particularly without, HF in a
randomized trial.
Limitations
This study is an observational post hoc analysis of a
randomized trial and should be considered hypothesis
generating. Dose and drug concentrations of digoxin were
not available during the study. Digoxin use was considered
at baseline and data regarding its use during the trial were
available only every 3 months in the study visit. Neverthe-
less, using digoxin as a time-variant covariate did not change
the key results. In addition, both methods of analyzing a
concomitant medication have their limitations.28 Given the
low rates of some end points, the multivariable models may
be overspeciﬁed. Nevertheless, to be consistent, similar
multivariate models were used throughout. With regard to
SCD, several important factors were not available in this
study including documentation of arrhythmia, family history
of SCD, and genetic tests; however, all SCD events were
adjudicated by an independent committee. The ENGAGE AF-
TIMI 48 trial included patients with AF who were at
moderate-high risk, and our results may not be generalized
to low-risk patients with AF. Nevertheless, this study is
based on the largest randomized controlled trial in patients
with AF. Finally, the association between digoxin and worse
clinical outcomes as demonstrated in the current analysis
was not demonstrated in the only prospective trial with
digoxin in patients with HF.29 However, this trial was limited
to patients in sinus rhythm, and no conclusions can be made
with regards to patients with AF.
Conclusions
In this observational study in patients with AF, digoxin use
was associated with worse clinical outcomes. In patients
with HF, digoxin use was associated with all-cause death,
cardiovascular death, SCD, HF death, and HF hospitaliza-
tions. In patients without HF, digoxin use was signiﬁcantly
associated with SCD. While the results in patients with HF
might be caused by residual confounding, our results
highlight the need to examine digoxin use in patients with
AF without HF, in a randomized controlled trial. Given the
availability of other rate-control agents, until the safety of
digoxin in patients with AF without HF has been established,
the use of the drug in this population should be undertaken
with great care, if at all.
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Table S1. Baseline characteristics by baseline heart failure status and digoxin use.    
 Heart failure (n=12124) 
 
No heart failure (n=8981) 
Characteristic- n (%)  Digoxin  
n=4502 (37%) 
 
No digoxin 
n=7622 (63%) 
P value Total 
 
 
Digoxin 
n=1825 (20%) 
No digoxin 
n=7156 (80%) 
P value Total 
Age, years- median (IQR) 69 (61-76) 70 (63-76) <0.001 70 (62-76) 75 (68-79) 75 (67-79) 0.36 75 (67-79) 
Female sex 1758 (39.0) 2818 (37.0) 0.02 4576 (37.7) 798 (43.7) 2666 (37.3) <0.001 3464 (38.6) 
Weight, kg- mean (SD) 82.8 (20.7)  86.2 (20.2) <0.001 84.9 (20.4) 80.1 (20.2) 83.1 (19.7) <0.001 82.5 (19.8) 
Region º 
     North America 
     Latin America 
     Western Europe 
     Eastern Europe 
     Asia-Pacific and SA 
 
586 (13.0)  
752 (16.7)  
402 (8.9)  
1967 (43.7)  
795 (17.7)  
 
1281 (16.8)  
934 (12.3)  
1026 (13.5)  
3458 (45.4)  
923 (12.1)  
<0.001  
1867 (15.4) 
1686 (13.9) 
1428 (11.8) 
5425 (44.7) 
1718 (14.2) 
 
568 (31.1) 
225 (12.3) 
331 (18.1) 
348 (19.1) 
353 (19.3) 
 
2246 (31.4) 
750 (10.5) 
1477 (20.6) 
1371 (19.2) 
1312 (18.3) 
0.04  
2814 (31.3) 
975 (10.9) 
1808 (20.1) 
1719 (19.1) 
1665 (18.5) 
White race (n=21104) 3481 (77.3) 6471 (84.9) <0.001 9952 (82.1) 1411 (77.3) 5704 (79.7) 0.02 7115 (79.2) 
Type of atrial fibrillation 
(n=21099) 
     Paroxysmal 
     Persistent 
     Permanent 
 
421 (9.4) 
1053 (23.4) 
3028 (67.3) 
 
2017 (26.5) 
1853 (24.3) 
3751 (49.2) 
<0.001  
2438 (20.1) 
2906 (24.0) 
6779 (55.9) 
 
292 (16.0) 
371 (20.3) 
1161 (63.7) 
 
2636 (36.9) 
1591 (22.2) 
2925 (40.9) 
<0.001  
2928 (32.6) 
1962 (21.9) 
4086 (45.5) 
Qualifying risk factor 
     Hypertension requiring 
     treatment 
     Age≥ 75 yr 
     Diabetes mellitus 
     Prior stroke or TIA 
 
4169 (92.6) 
 
1337 (29.7) 
1439 (32.0) 
999 (22.2) 
 
7228 (94.8) 
 
2478 (32.5) 
2242 (29.4) 
1531 (20.1) 
 
<0.001 
 
0.001 
0.003 
0.006 
 
11397 (94.0) 
 
3815 (31.5) 
3681 (30.4) 
2530 (20.9) 
 
1684 (92.3) 
 
942 (51.6) 
890 (48.8) 
707 (38.7) 
 
6673 (93.3) 
 
3717 (51.9) 
3053 (42.7) 
2736 (38.2) 
 
0.14 
 
0.80 
<0.001 
0.69 
 
8357 (93.1) 
 
4659 (51.9) 
3943 (43.9) 
3443 (38.3) 
CHADS2 score 
* 
     Mean (SD) 
     4-6 
 
3.0 (1.1) 
1162 (25.8) 
 
3.0 (1.0) 
1963 (25.8) 
 
0.84 
0.95 
 
3.0 (1.0) 
3125 (25.8) 
 
2.7 (0.9) 
369 (20.2) 
 
2.6 (0.8) 
1274 (17.8) 
 
0.03 
0.02 
 
2.7 (0.8) 
1643 (18.3) 
 by guest on June 21, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
CHA2DS2-VASc score 
* 
     Mean (SD) 
     4-9 
 
4.4 (1.5) 
3157 (70.1) 
 
4.5 (1.5) 
5524 (72.5) 
 
0.005 
0.006 
 
4.5 (1.5) 
8681 (71.6) 
 
4.2 (1.2) 
1314 (72.0) 
 
4.1 (1.2) 
4924 (68.8) 
 
0.001 
0.008 
 
4.2 (1.2) 
6238 (69.5) 
HAS-BLED score * 
     Mean (SD) 
     ≥ 3 
 
2.3 (0.9) 
1749 (38.8) 
 
2.4 (1.0) 
3343 (43.9) 
 
<0.001 
<0.001 
 
2.4 (1.0) 
5092 (42.0) 
 
2.6 (0.9) 
894 (49.0) 
 
2.7 (1.0) 
3816 (53.3) 
 
<0.001 
<0.001 
 
2.7 (1.0) 
4710 (52.4) 
Coronary artery disease 
(n=21102) 
1600 (35.5) 3163 (41.5) <0.001 4763 (39.3) 404 (22.1) 1856 (25.9) 
<0.001 2260 (25.2) 
Prior myocardial infarction 581 (12.9) 1143 (15.0) 0.002 1724 (14.2) 123 (6.7) 586 (8.2) 0.04 709 (7.9) 
Ejection fraction † 
    < 30% 
     30-39% 
     40-49% 
     ≥ 50%    
 
388 (11.3) 
651 (18.9) 
942 (27.3) 
1465 (42.5) 
 
362 (6.0) 
779 (13.0) 
1452 (24.2) 
3403 (56.8) 
<0.001  
750 (7.9) 
1430 (15.1) 
2394 (25.4) 
4868 (51.6) 
 
10 (0.9) 
22 (1.9) 
116 (9.9) 
1023 (87.4) 
 
22 (0.4) 
69 (1.4) 
358 (7.2) 
4502 (90.9) 
<0.001  
32 (0.5) 
91 (1.5) 
474 (7.7) 
5525 (90.2) 
NYHA III, IV ‡ (n=11988) 1220 (27.4) 1415 (18.8) <0.001 2635 (22.0) NA NA  NA 
Peripheral arterial disease 
(n=21096) 
158 (3.5) 355 (4.7) 0.002 513 (4.2) 53 (2.9) 275 (3.8) 
0.06 328 (3.7) 
Former/current smoker 
(n=21098) 
1722 (38.2) 3049 (40.0) 0.05 4771 (39.4) 753 (41.3) 3124 (43.7) 
0.06 3877 (43.2) 
COPD 475 (10.6) 725 (9.5) 0.06 1200 (9.9) 151 (8.3) 430 (6.0) <0.001 581 (6.5) 
Mitral valve disease 
(n=20983) 
1755 (39.2) 2911 (38.4) 0.42 4666 (38.7) 521 (28.8) 2061 (29.0) 
0.87 2582 (28.9) 
Aortic valve disease 
(n=21014) 
681 (15.2) 1248 (16.5) 0.06 1929 (16.0) 226 (12.5) 979 (13.7) 
0.17 1205 (13.5) 
Prior electrical cardioversion 
for AF (n=21104) 
611 (13.6) 1505 (19.7) <0.001 2116 (17.5) 384 (21.0) 1291 (18.0) 0.003 1675 (18.7) 
Charlson comorbidity index, 
mean (SD) 
3.1 (1.0) 3.1 (1.0) 0.46 3.1 (1.0) 2.5 (1.0) 2.4 (1.0) 0.001 2.4 (1.0) 
Heart rate (BPM), mean (SD) 
(n=21074) 
78.1 (14.2) 74.1 (14.0) <0.001 75.6 (14.2) 74.5 (13.7) 71.9 (13.4) 
<0.001 72.4 (13.5) 
Hypertrophy per ECG 
(n=20950) 
1124 (25.1) 1576 (20.8) <0.001 2700 (22.4) 187 (10.3) 550 (7.8) 
<0.001 737 (8.3) 
Vitamin K antagonist 
experienced § (n=21104) 
2583 (57.4) 4290 (56.3) 0.25 6873 (56.7) 1335 (73.2) 4233 (59.2) <0.001 5568 (62.0) 
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Medication at randomization 
     Aspirin (n=21101) 
     Lipid lowering  
     Antiarrhythmics 
          Class I 
          Class II (beta-blockers) 
          Class III 
          Class IV 
     Diuretics 
     RAAS inhibitor 
 
1216 (27.0) 
1649 (36.6) 
 
53 (1.2) 
3106 (69.0) 
458 (10.2) 
336 (7.5) 
3562 (79.1) 
3290 (73.1) 
 
2365 (31.0) 
3584 (47.0) 
 
343 (4.5) 
5565 (73.0) 
1595 (20.9) 
488 (6.4) 
5176 (67.9) 
5357 (70.3) 
 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
0.02 
<0.001 
0.001 
 
3581 (29.5) 
5233 (43.2) 
 
396 (3.3) 
8671 (71.5) 
2053 (16.9) 
824 (6.8) 
8738 (72.1) 
8647 (71.3) 
 
414 (22.7) 
909 (49.8) 
 
42 (2.3) 
1013 (55.5) 
130 (7.1) 
293 (16.1) 
883 (48.4) 
1023 (56.1) 
 
2185 (30.5) 
3940 (55.1) 
 
455 (6.4) 
4300 (60.1) 
951 (13.3) 
788 (11.0) 
3035 (42.4) 
4236 (59.2) 
 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
0.02 
 
2599 (28.9) 
4849 (54.0) 
 
497 (5.5) 
5313 (59.2) 
1081 (12.0) 
1081 (12.0) 
3918 (43.6) 
5259 (58.6) 
CrCl (ml/min), Median (IQR) 71.8 (54.5-
95.3) 
72.8 (55.1-
94.4) 
0.65 72.4 (54.8-
94.6) 
67.1 (51.7-
87.9) 
67.9 (53.0-
87.7) 
0.24 67.7 (52.8-
87.7) 
Dose reduction at 
randomization 
1211 (26.9) 1705 (22.4) <0.001 2916 (24.1) 568 (31.1) 1872 (26.2) <0.001 2440 (27.2) 
Randomized treatment 
     High dose Edoxaban 
     Low dose Edoxaban 
     Warfarin 
 
1487 (33.0) 
1464 (32.5) 
1551 (34.5) 
 
2610 (34.2) 
2515 (33.0) 
2497 (32.8) 
0.15  
4097 (33.8) 
3979 (32.8) 
4048 (33.4) 
 
591 (32.4) 
609 (33.4) 
625 (34.2) 
 
2347 (32.8) 
2446 (34.2) 
2363 (33.0) 
0.60  
2938 (32.7) 
3055 (34.0) 
2988 (33.3) 
 
Data shown are n (%) unless otherwise indicated 
 
Abbreviations- BPM, beats per minute; CrCl, creatinine clearance; CV, cardiovascular; ECG, electrocardiogram; NYHA, New York heart 
association functional class; RAAS, renin angiotensin aldosterone system; SA, South Africa; SCD, sudden cardiac death; SD, standard 
deviation; TIA, transient ischemic attack. 
 
* CHADS2 score- see reference [27]; CHA2DS2-VASc score- see reference [28]; HAS-BLED score- see reference [29].  
º Percentages are for each region except for the Total column.  
† Ejection fraction was unknown for 5541 patients (heart failure- 2682 patients; no heart failure- 2859 patients).  
 ‡ NYHA class at baseline was reported only in patients with HF.  
§ Vitamin K antagonist experienced denotes ≥60 consecutive days of treatment with a vitamin K antagonist at any time prior to enrollment. 
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Table S2. Clinical outcomes by digoxin use and type of HF at baseline.  
 Systolic heart failure (n=5027) * Diastolic heart failure (n=4150) 
Endpoint-  
n (%/year) 
Digoxin 
(n=1728) 
No digoxin 
(n=3299) 
Adj HR ‡ 
(95% CI) 
Digoxin 
(n=1716) 
No digoxin 
(n=2434) 
Adj HR ‡ 
(95% CI) 
All cause death 272 (5.9) 349 (3.9) 1.33 (1.12-1.58) 283 (6.2) 325 (4.9) 1.14 (0.96-1.35) 
CV death 
     SCD 
     HF/cardiogenic  
     shock death 
214 (4.6) 
98 (2.1) 
69 (1.5) 
251 (2.8) 
115 (1.3) 
53 (0.6) 
1.39 (1.13-1.69) 
1.34 (0.99-1.81) 
2.20 (1.48-3.29) 
228 (5.0) 
119 (2.6) 
61 (1.3) 
244 (3.7) 
108 (1.6) 
68 (1.0) 
1.20 (0.99-1.45) 
1.33 (1.00-1.76) 
1.17 (0.79-1.72) 
Non-CV death 58 (1.3) 98 (1.1) 1.15 (0.81-1.64) 55 (1.2) 81 (1.2) 0.95 (0.64-1.40) 
Stroke/ SSE 90 (2.0) 155 (1.8) 1.03 (0.77-1.36) 76 (1.7) 104 (1.6) 0.99 (0.73-1.35) 
HF hospitalizations 228 (5.4) 328 (3.9) 1.17 (0.97-1.41) 284 (6.8) 300 (4.9) 1.37 (1.14-1.64) 
MI 32 (0.7) 66 (0.8) 0.81 (0.51-1.29) 28 (0.6) 68 (1.1) 0.71 (0.43-1.18) 
 
CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; MI, myocardial infarction; SCD, sudden cardiac death; SSE, 
stroke or systemic embolism. 
 
Type of HF was unknown in 2634 patients.   
 
*Systolic HF included patients with systolic HF (n=2875) and both systolic and diastolic HF (n=2152).  
‡ Hazard ratios are adjusted for age, weight, sex, region, race, creatinine, atrial fibrillation type, hypertension, diabetes mellitus, history of 
stroke or transient ischemic attack, history of coronary artery disease, prior myocardial infarction, history of peripheral artery disease, smoking 
status, increased risk of falling, left ventricle ejection fraction, mitral valve disease, aortic valve disease, prior electrical cardioversion, left 
ventricular hypertrophy, previous use of vitamin K antagonists ≥ 60 days prior to randomization, lipid lowering medications, class I, II, III 
antiarrhythmics, renin-angiotensin-aldosterone, randomized treatment group, heart rate, history of COPD, diuretic use at randomization. 
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Table S3. Hazard ratios (95% CIs) of digoxin use in patients without heart failure at baseline using digoxin as a time-variant covariate 
(digoxin "on", or digoxin "on/off" methods *).   
 
Endpoint Digoxin "on" * 
Adj HR (95% CI) ‡  
Digoxin "on/off" * 
Adj HR (95% CI) ‡ 
All cause death 1.71 (0.95-3.07) 1.17 (0.60-2.27) 
CV death 
     SCD 
     Non SCD 
1.81 (0.85-3.85) 
5.53 (1.66-18.41) 
0.76 (0.24-2.36) 
1.18 (0.49-2.81) 
4.45 (1.37-14.44) 
0.21 (0.03-1.64) 
Non-CV death 1.68 (0.64-4.41) 1.18 (0.41-3.45) 
Stroke/ SSE 1.36 (1.06-1.74) 0.96 (0.72-1.27) 
HF hospitalizations 1.92 (1.51-2.44) 1.80 (1.40-2.32) 
MI 1.55 (1.08-2.23) 1.34 (0.90-1.99) 
CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; MI, myocardial infarction; SCD, sudden cardiac death; SSE, 
stroke or systemic embolism. 
 
Data presented are for 8806 patients.  
 
* Digoxin use was reported at each study visit (every 3 months) and was regarded as a time-dependent variable using 2 methods: In the first, if 
digoxin was started during follow-up, the patient was regarded as being on digoxin throughout the trial (digoxin "on"), while in the second, the 
patient was regarded as being on or off digoxin per the status of digoxin use every 3 months (digoxin "on/off"). 
 
‡ Hazard ratios are adjusted for age, weight, sex, region, race, creatinine, atrial fibrillation type, hypertension, diabetes mellitus, history of 
stroke or transient ischemic attack, history of coronary artery disease, prior myocardial infarction, history of peripheral artery disease, smoking 
status, increased risk of falling, left ventricle ejection fraction, mitral valve disease, aortic valve disease, prior electrical cardioversion, left 
ventricular hypertrophy, previous use of vitamin K antagonists ≥ 60 days prior to randomization, lipid lowering medications, class I, II, III 
antiarrhythmics, renin-angiotensin-aldosterone, diuretic use, randomized treatment group, heart rate, chronic obstructive pulmonary disease.  
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